Multiple Myeloma Market | Size, Share, Growth

Multiple Myeloma Market Research Report

Published: 2025 - January

Report Code: VMR-17545

Region: Global

Request Sample

Customization

Ask an Expert

Enquire Enquire Before Buying

Multiple Myeloma Market Analysis

The Multiple Myeloma Market represents a dynamic and evolving segment of oncology, addressing a complex hematological malignancy characterized by abnormal plasma cell proliferation in the bone marrow. This market encompasses an extensive pipeline of innovative therapies and a range of marketed drugs, highlighting the intense focus on precision medicine, targeted therapies, and patient-centric treatment options.

Disruptive Impact and Opportunities:

The multiple myeloma landscape is undergoing a disruptive transformation, driven by advancements in novel treatment modalities such as CAR-T cell therapies, bispecific antibodies, and next-generation immunomodulatory drugs. These innovations offer unprecedented opportunities for improving patient outcomes, streamlining treatment pathways, enhancing safety profiles, and unlocking a substantial unmet medical need. Emerging drugs like Venetoclax, Ciltacabtagene Autoleucel, REGN5458, and Iberdomide exemplify the commitment to addressing disease progression and resistance, while marketed therapies such as Darzalex, Sarclisa, and Abecma continue to redefine standards of care.

Multiple Myeloma Market Segmentation - Emerging Drugs

Venetoclax
Ciltacabtagene Autoleucel
REGN5458
Iberdomide

Multiple Myeloma Market Segmentation - Marketed Drugs

Darzalex
Sarclisa
Abecma

Key Companies:

Sanofi
Janssen Biotech
Bristol-Myers Squibb
Karyopharm Therapeutics
GlaxoSmithKline

Multiple Myeloma Market Segmentation - By Type

Therapies
- Immunomodulatory Drugs (IMiDs)
  - Lenalidomide
  - Pomalidomide
  - Thalidomide
- Proteasome Inhibitors
  - Bortezomib
  - Carfilzomib
  - Ixazomib
- Monoclonal Antibodies
  - Daratumumab
  - Isatuximab
  - Elotuzumab
- Histone Deacetylase (HDAC) Inhibitors
  - Panobinostat
- Antibody-Drug Conjugates (ADCs)
  - Belantamab Mafodotin
- Bispecific T-Cell Engagers (BiTEs)
  - Teclistamab
- CAR-T Cell Therapies
  - Idecabtagene Vicleucel
  - Ciltacabtagene Autoleucel
- Alkylating Agents
  - Melphalan
  - Cyclophosphamide
- Corticosteroids
  - Dexamethasone
  - Prednisone

Multiple Myeloma Market Segmentation - By Administration Type

· Oral

Tablets
Capsules

· Injectable

Intravenous (IV)
Subcutaneous (SC)

What’s in It for You?

Comprehensive insights into emerging therapies, including CAR-T and bispecific antibody technologies.
An analysis of existing marketed drugs and their competitive positioning in the treatment paradigm.
Opportunities to identify unmet needs, market gaps, and potential partnerships.
A deep dive into key players' strategies and their impact on innovation and commercialization.
Data-driven perspectives to aid portfolio optimization, market entry planning, and long-term investment decisions.

Multiple Myeloma Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)

1 Multiple Myeloma Market - Executive Summary

1.1. Introduction

1.2. Objectives

1.3. Key Findings

1.3.1. Market Size 2022 & 2032: By Key Country (10MM)

1.3.2. Global Market Size 2022 & 2032: By Key Segment

1.3.3. Key Investments & Startup Analysis

1.4. Research Methodology

2 Understanding the Disease

2.1. Disease Overview

2.2. Classification

2.3. Signs and Symptoms

2.4. Risk Factors

2.5. Causes

2.6. Disease Biology & Digital Innovations

2.7. Stages & Staging System

2.8. Diagnostic Algorithm

2.9. Current Treatment Practices & Algorithm

2.10. Current Standard of Care and Treatment Gaps

2.11. Patient Demographics and Treatment Pathways

3 Guidelines

4 Unmet Needs

5 Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 10MM

5.3. Epidemiology Scenario: 10MM

5.4. U.S. Epidemiology Scenario

5.5. EU-5 Epidemiology

5.5.1. U.K. Epidemiology Scenario

5.5.2. Germany Epidemiology Scenario

5.5.3. France Epidemiology Scenario

5.5.4. Italy Epidemiology Scenario

5.5.5. Spain Epidemiology Scenario

5.6. Japan Epidemiology Scenario

5.7. China Epidemiology Scenario

5.8. Australia Epidemiology Scenario

5.9. India Epidemiology Scenario

6 Real-world Data & Real-world Evidence

7 Drug Development Landscape

7.1. Existing Key Drug Candidate Profiles/ Marketed Therapies

7.1.1. Blenrep (Belantamab Mafodotin /GSK2857916)

7.1.1.1. Product Description

7.1.1.2. Regulatory Milestones

7.1.1.3. Other Developmental Activities

7.1.1.4. Pivotal Clinical Trials

7.1.1.5. Ongoing Current Pipeline Activity

7.1.2. Abecma (Idecabtagene vicleucel/bb2121/ ide-cel)

7.1.2.1. Product Description

7.1.2.2. Regulatory Milestones

7.1.2.3. Other Developmental Activities

7.1.2.4. Pivotal Clinical Trials

7.1.2.5. Ongoing Current Pipeline Activity

7.1.3. Pepaxto (melflufen/ melphalan flufenamide)

7.1.3.1. Product Description

7.1.3.2. Regulatory Milestones

7.1.3.3. Other Developmental Activities

7.1.3.4. Pivotal Clinical Trials

7.1.3.5. Ongoing Current Pipeline Activity

7.1.4. Sarclisa (Isatuximab)

7.1.4.1. Product Description

7.1.4.2. Regulatory Milestones

7.1.4.3. Other Developmental Activities

7.1.4.4. Pivotal Clinical Trials

7.1.4.5. Ongoing Current Pipeline Activity

7.1.5. Xpovio (Selinexor)

7.1.5.1. Product Description

7.1.5.2. Regulatory Milestones

7.1.5.3. Other Developmental Activities

7.1.5.4. Pivotal Clinical Trials

7.1.5.5. Ongoing Current Pipeline Activity

7.2. Competitive Analysis and Differentiation

7.3. Overview of Similar/Competing Drugs in Clinical Trials

7.4. Future Trends and Emerging Drugs

7.4.1. Venetoclax (ABT-199)

7.4.1.1. Product Description

7.4.1.2. Clinical Development

7.4.1.3. Safety and Efficacy

7.4.2. Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528/ JNJ-68284528/ LCAR-B38M)

7.4.2.1. Product Description

7.4.2.2. Clinical Development

7.4.2.3. Safety and Efficacy

7.4.3. REGN5458

7.4.3.1. Product Description

7.4.3.2. Clinical Development

7.4.3.3. Safety and Efficacy

7.4.4. Iberdomide (CC-220)

7.4.4.1. Product Description

7.4.4.2. Clinical Development

7.4.4.3. Safety and Efficacy

8 Regulatory Strategy and Potential Challenges

8.1. Regulatory Pathways in Key Markets

8.2. Anticipated Regulatory Hurdles and Mitigation Strategies

8.3. Case Studies in Oncology Drug Regulation

8.4. Impact of Potential Changes to Regulatory Framework

9 Commercial Landscape

9.1. Market Size & Growth Rates

9.2. Key Approvals & Anticipated Loss of Exclusivity

9.3. PESTLE & Porter’s Five Forces Analysis

9.4. Market Shares, Positioning/Ranking

9.5. Market Drivers

9.6. Identification of Threats

9.7. Digital Evolution in Commercialization

10 Market Segmentation

10.1. Market by Type

10.1.1. Smouldering Multiple Myeloma

10.1.2. Active Multiple Myeloma

11 Pricing, Reimbursement, and Access

11.1. Competitive Pricing Analysis

11.2. Reimbursement Landscape and Challenges

11.3. Strategies for Market Access and Equity

11.4. Patient Spending/Expenditure Analysis

12 Future Trends, Disruptions, and Opportunities

12.1. Analysis of Emerging Trends

12.2. Technological Impact

12.3. Impact of Potential Market Disruptors

12.4. Opportunities for Future Development and Expansion

12.5. Considerations for Investment Opportunities

13 Global Market Dynamics

13.1. Regional Regulatory Disparities

13.2. Cross-Border Partnership Strategies

13.3. Global Supply Chain Dynamics

13.4. Case Studies: Success and Failure in Global Markets

13.5. Strategies for Global Expansion and Localization

14 Company Profiles

14.1. Sanofi

14.2. Karyopharm Therapeutics

14.3. AbbVie

14.4. Takeda Pharmaceutical

14.5. Bristol-Myers Squibb

14.6. RAPA Therapeutics

14.7. Pfizer

14.8. AstraZeneca

14.9. Johnson & Johnson

14.10. Merck

Download Sample

Full Name *

Job Title *

Company *

Email *

Phone *

Country *

Message

↻

The field with (*) is required.

Choose License Type

Excel Data Pack

2500

Single User

4250

Multi User

5250

Corporate User

6900